Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Éric Pujade-Lauraine(Eau de Paris (France)), Thibault De La Motte Rouge(Inserm), Alla Lisyanskaya(City Clinical Oncology Center), Jean‐Pierre Lotz, Diane Provencher(Centre Hospitalier de l’Université de Montréal), Michael Friedländer(Prince of Wales Hospital), Val Gebski(The University of Sydney), Keiichi Fujiwara(Saitama Medical University), Tomasz Byrski(International Hereditary Cancer Center), Tomasz Huzarski(International Hereditary Cancer Center), Giovanni Scambia(Agostino Gemelli University Polyclinic), Andrew R. Clamp, Elizabeth Lowe(AstraZeneca (United States)), Jacob Korach(Tel Aviv University), Manuel Rodrigues(Inserm), Coraline Dubot(Institut Curie), Nicolas Pécuchet, Joyce F. Liu(Duke University), Jacques Médioni, Frédèric Selle, Susana Banerjee(Royal Marsden NHS Foundation Trust), Kenji Tamura(Unknown), Patricia Pautier(Université Paris-Saclay), Amit M. Oza(Ontario Institute for Cancer Research), Isabelle Ray‐Coquard(Centre Léon Bérard), Philipp Harter(Kliniken Essen-Mitte), Jonathan A. Ledermann(London Cancer), Sandro Pignata(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Ralph Bloomfield(AstraZeneca (United Kingdom)), Mayu Yunokawa(Japanese Foundation For Cancer Research), Clare L. Scott(Walter and Eliza Hall Institute of Medical Research), Richard T. Penson(Massachusetts General Hospital), Andrés Poveda(Hospital Quirónsalud Barcelona), Nicoletta Colombo(University of Milano-Bicocca), Aleix Prat Aparicio, A. Poveda Velasco(Hospital Quirónsalud Barcelona), Laura Vidal Boixader, Maria Ornella Nicoletto, Fiona Nussey
Cited by 1,884
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
|The Lancet|2014|1.8k
<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas
|New England Journal of Medicine|2010|1.7k